<DOC>
	<DOC>NCT01461759</DOC>
	<brief_summary>The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. Therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.</brief_summary>
	<brief_title>Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirmed chemotherapy naïve endometrial cancer One of following histology Endometrioid, UPSC, CCCa, squamous, adenosquamous, mixed FIGO stage IVb or recurrent endometrial cancer (incurable by surgery and/or RT) At least one measurable lesion by RECIST on CT ECOG PS: 02 Age: 2075 Adequate organ function BM: ANC≥1,000/mm3, Plt≥100X103/mm3 Kidney: Creatinine&lt;1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT&lt; 3×UNL, T bil&lt;1.5 mg/ mm3 Informed Consent Contraception during study period Previous chemotherapy RT, hormone therapy, or immunotherapy within 1 month Other malignant disease Uncontrolled medical disease Infection requiring antibiotics Symptomatic CHF, RF, Angina, Arrhythmia, etc. Neurosis or psychosis Pregnancy, breastfeeding Etc.</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>